Reports that a routine test to detect ovarian cancer may be available in late 2003. Advantages of this test, including early detection of the disease; Escalation of the debate over cancer-screening tests; Potential problems of their usage, such as false positives leading to unnecessary surgery....
Ovarian cancer is the uncontrolled proliferation of cells in the ovaries, the reproductive organ responsible for egg production in women. While it can impact women of all ages and ethnicities, mutations in a gene linked tobreast cancercalled theBRCAgene, as well as age, dramatically increase the ...
“The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer,” said Mor. “We hope this test will become the standard of care for women having routine examinations.” Epithelial ovarian cancer is the leading cause of gynecologic...
such as ultrasound or detection of the protein CA125, have a high false positive rate for ovarian cancer. And clinical trials have found that when these tests are used to try to detect early-stage ovarian cancer, they do not have a meaningful impact...
, part of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), the world's largest ovarian cancer screening trial, are published in the Journal of Clinical Oncology."There is currentlyno national screening programme for ovarian cancer, as research to date has been unable to provide...
Ovarian canceroften develops without any obvious symptoms or early warning signs, making an effective screening test especially important. "Because of where it is in the body, it classically presents later. By the time there's symptoms, it's a big cancer and it's too hard to actually cure,...
Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells cancer cells and could sensitize ovarian cancer cells to TRAIL treatment, either therapeutically applied or endogenously produced by cells of the immune system... A Brüning,M Vogel,P Burger,... - 《Biochemical & Biophysical ...
A new blood test allowing doctors to predict which ovarian cancer patients will respond to particular types of treatment is a step closer following a new study by Manchester scientists. Researchers from The University of Manchester and The Christie NHS Foundation Trust - both part of Manchester ...
The author offers insights on using a serum-based ovarian cancer test called OVA1, which was approved by the U.S. Food and Drug Administration (FDA) in September 2009. She says that such test is a supplement to clinical decision making for women diagnosed with adnexal mass who consider unde...
Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialised gynaecologicalcancerunit, but this only happens for a minority of women in Europe and the US at present. Apart from the tumour type, the choice of treatment sometimes has to...